American International Group Inc. Acquires 2,120 Shares of Kite Pharma, Inc. (KITE)

American International Group Inc. raised its holdings in shares of Kite Pharma, Inc. (NASDAQ:KITE) by 7.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,451 shares of the biopharmaceutical company’s stock after buying an additional 2,120 shares during the period. American International Group Inc. owned about 0.06% of Kite Pharma worth $5,835,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of KITE. Dimensional Fund Advisors LP purchased a new stake in Kite Pharma in the 1st quarter worth approximately $5,198,000. Bank of Montreal Can raised its holdings in shares of Kite Pharma by 17.0% during the 2nd quarter. Bank of Montreal Can now owns 8,898 shares of the biopharmaceutical company’s stock valued at $923,000 after purchasing an additional 1,293 shares in the last quarter. Aperio Group LLC raised its holdings in shares of Kite Pharma by 35.9% during the 2nd quarter. Aperio Group LLC now owns 6,279 shares of the biopharmaceutical company’s stock valued at $651,000 after purchasing an additional 1,660 shares in the last quarter. Shell Asset Management Co. bought a new position in shares of Kite Pharma during the 2nd quarter valued at $633,000. Finally, Strs Ohio raised its holdings in shares of Kite Pharma by 45.6% during the 2nd quarter. Strs Ohio now owns 8,300 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 87.72% of the company’s stock.

Several research analysts recently commented on the stock. SunTrust Banks downgraded shares of Kite Pharma from a “buy” rating to a “hold” rating in a report on Monday, August 28th. BTIG Research downgraded shares of Kite Pharma from a “buy” rating to a “neutral” rating in a report on Monday, August 28th. Guggenheim lowered shares of Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 price target on the stock. in a research report on Monday, August 28th. Canaccord Genuity lowered shares of Kite Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. Finally, Wedbush upgraded shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a research report on Tuesday, August 29th. Thirteen investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $94.68.

In related news, Chairman Arie Belldegrun sold 26,347 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $4,733,502.02. Following the completion of the transaction, the chairman now owns 135,507 shares in the company, valued at $24,345,187.62. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Shawn Tomasello sold 4,203 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $755,110.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 48,936 shares of company stock valued at $8,791,842. 14.00% of the stock is currently owned by insiders.

Kite Pharma, Inc. (KITE) opened at $179.99 on Wednesday. Kite Pharma, Inc. has a 12 month low of $39.82 and a 12 month high of $179.99.

WARNING: “American International Group Inc. Acquires 2,120 Shares of Kite Pharma, Inc. (KITE)” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/12/13/american-international-group-inc-has-5-84-million-holdings-in-kite-pharma-inc-kite.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply